Interleukin 21 News and Research

RSS
IL-21 protein is a major part of immune response to chronic infections in the central nervous system

IL-21 protein is a major part of immune response to chronic infections in the central nervous system

Study reveals how B cells react to SARS-CoV-2

Study reveals how B cells react to SARS-CoV-2

New method helps pinpoint new potential therapeutic targets for lupus

New method helps pinpoint new potential therapeutic targets for lupus

Combination produces more proliferative, enduring central memory T cells for cellular therapy

Combination produces more proliferative, enduring central memory T cells for cellular therapy

Research findings may pave way for innovative treatments of multiple sclerosis

Research findings may pave way for innovative treatments of multiple sclerosis

Oncologists combine two different types of immunotherapy to successfully treat metastatic melanoma

Oncologists combine two different types of immunotherapy to successfully treat metastatic melanoma

Scientists describe interplay of four molecules that trigger, govern antibody production in immune cells

Scientists describe interplay of four molecules that trigger, govern antibody production in immune cells

Lupus Foundation of America announces Career Development Award and new summer fellowships

Lupus Foundation of America announces Career Development Award and new summer fellowships

Research describes advantages of new vaccine adjuvant

Research describes advantages of new vaccine adjuvant

New Crohn’s disease therapy on its way

New Crohn’s disease therapy on its way

Researchers investigate mechanism of immune system to decipher gut-dwelling worms

Researchers investigate mechanism of immune system to decipher gut-dwelling worms

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

ZymoGenetics second-quarter net loss declines to $3.8 million

ZymoGenetics second-quarter net loss declines to $3.8 million

ZymoGenetics' IL-21 Phase 2 clinical trial in metastatic melanoma meets primary endpoint

ZymoGenetics' IL-21 Phase 2 clinical trial in metastatic melanoma meets primary endpoint

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

ZymoGenetics restructures license and collaboration agreements on RECOTHROM

ZymoGenetics restructures license and collaboration agreements on RECOTHROM

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients

BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients

Phase 2 clinical study of PEG-Interferon lambda commenced

Phase 2 clinical study of PEG-Interferon lambda commenced

Phase 1b clinical trial results of PEG-Interferon lambda to be presented

Phase 1b clinical trial results of PEG-Interferon lambda to be presented